Carmen Black, MD, Emma Lo, MD, and Keith Gallagher, MD
Violence perpetrated against unarmed patients is common in health care, and evidence-based safety measures are needed to acknowledge and eradicate clinical violence.
AMA J Ethics. 2022;24(3):E218-225. doi:
10.1001/amajethics.2022.218.
William F. Parker, MD, MS and Marshall H. Chin, MD, MPH
Given organ scarcity, transplantation programs state that patient promises of compliance cannot be taken at face value, excluding candidates who are deemed untrustworthy.
AMA J Ethics. 2020;22(5):E408-415. doi:
10.1001/amajethics.2020.408.
Jonathan Alhalel, Nicolás Francone, Sharon Post, Catherine A. O’Brian, PhD, and Melissa A. Simon, MD, MPH
Underrepresentation of individuals with limited English proficiency who speak Spanish is ongoing in phase 3 biomedical clinical trials and exacerbates health inequity.
AMA J Ethics. 2022;24(4):E319-325. doi:
10.1001/amajethics.2022.319.
Spread of health misinformation by health professionals who also hold government positions represents a long-standing problem exacerbated during the COVID-19 pandemic.
AMA J Ethics. 2023;25(3):E210-218. doi:
10.1001/amajethics.2023.210.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022;24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
AMA J Ethics. 2022;24(11):E1083-1090. doi:
10.1001/amajethics.2022.1083.